C. Jimmy Lin, MD, PhD, MHS is the Chief Scientific Officer (CSO), Oncology at Natera and a TED Fellow. He has a long history as a pioneer in cancer genomics. Through his Rare Genomics Institute, Jimmy Lin has created crowd-funding opportunities and new therapies for rare genetic diseases that don’t attract major research dollars. He led the clinical genomics program at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Previously, at Johns Hopkins and Washington University in St. Louis, Lin was part of one of the first clinical genomics labs in academia and led the computational analyses of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma and melanoma. Lin has published in top academic journals, such as Science, Nature and Cell, and he has been an expert in national and international media outlets, such as New York Times, Forbes, Bloomberg Businessweek, The Washington Post, and the Financial Times.